Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
cerliponase_alfa
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinicalTrials |
Phase 2/3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Brineura
|
| gptkbp:issuedBy |
intracerebroventricular_injection
|
| gptkbp:lastProduced |
2017
|
| gptkbp:manufacturer |
gptkb:BioMarin_Pharmaceutical
|
| gptkbp:sideEffect |
headache
fever vomiting seizures irritability |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
children_with_CLN2_disease
|
| gptkbp:triggerType |
enzyme replacement therapy
|
| gptkbp:usedFor |
treatment_of_Batten_disease
|